CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,149 enrolled
Drug / intervention
REGN10933+REGN10987 combination therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04666441
NCT04666441Phase 2Completed
CompareCT.gov

A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection

Regeneron Pharmaceuticals·interventional·Posted Dec 14, 2020·Updated Apr 8, 2022

In Brief

A Phase 2 clinical trial evaluating REGN10933+REGN10987 combination therapy and Placebo for COVID-19. Completed, enrolled 1,149 participants across 57 sites.

Detailed Summary

The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: * To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo * To assess the concentrations of REGN10933 and REGN10987 in serum over time * To assess the immunogenicity of REGN10933 and REGN10987

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 14, 2020
Enrollment StartDec 15, 2020
Primary CompletionMar 4, 2021
Study CompletionSep 21, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.5 years ago

Interventions

REGN10933+REGN10987 combination therapydrug

Administered IV or SC single dose

Placebodrug

Administered IV or SC single dose to match